European AIDS Vaccine Initiative 2020

**Project ID**: 681137

**Funded under**: H2020-EU.3.1.2. - Preventing disease

**From** 2015-11-01 to 2020-10-31, ongoing project | [EAVI2020 Website](#)

### Project details

<table>
<thead>
<tr>
<th>Total cost:</th>
<th>Topic(s):</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>EU contribution:</th>
<th>Call for proposal:</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 22 948 022,25</td>
<td>H2020-PHC-2015-single-stage_RTD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Coordinated in:</th>
<th>Funding scheme:</th>
</tr>
</thead>
<tbody>
<tr>
<td>United Kingdom</td>
<td>RIA - Research and Innovation action</td>
</tr>
</tbody>
</table>

### Objective

HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradication. However despite 30 years of research, we do not have a vaccine capable of protecting from HIV-1 infection or impacting on disease progression. This in part represents the challenge of identifying immunogens and vaccine modalities with reduced risk of failure in late stage development. To overcome this bottleneck some of the most competitive research groups in vaccine discovery from European public institutions and biotechs from 9 EU countries together with top Australian and Canadian groups and US collaborators, have agreed to join forces in EAVI, providing a pool of international expertise at the highest level. EAVI2020 will provide a platform for the discovery and selection of several new, diverse and novel preventive and/or therapeutic vaccine candidates for HIV/AIDS. Emphasis will be placed on early rapid, iterative, small Experimental medicine (EM) human vaccine studies to select and refine the best immunogens, adjuvants, vectors, homologous and heterologous prime–boost schedules, and determine the impact of host factors such as gender and genetics. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To shift the “risk curve” in product development we will develop innovative risk prediction methods, specifically designed to reduce the risk associated with late stage preventive or therapeutic vaccine failure, increasing the chance of discovery of an effective vaccine.

### Related information

**Report Summaries**

Periodic Reporting for period 2 - EAVI2020 (European AIDS Vaccine Initiative 2020)
Coordinator

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
SW7 2AZ LONDON
United Kingdom

EU contribution: EUR 6 122 541,25

Activity type: Higher or Secondary Education Establishments
Contact the organisation

Participants

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
WELLINGTON SQUARE UNIVERSITY OFFICES
OX1 2JD OXFORD
United Kingdom

EU contribution: EUR 2 300 415

Activity type: Higher or Secondary Education Establishments
Contact the organisation

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
RUE DE TOLBIAC 101
75654 PARIS
France

EU contribution: EUR 1 140 062,50

Activity type: Research Organisations
Administrative contact: Laurie Louis-Joseph
Tel.: +33 1 45 17 29 32
Fax: +33 1 45 17 29 11
Contact the organisation

FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA
CARRETERA DE CANYET
08916 BARCELONA
Spain

EU contribution: EUR 1 998 031,25

Activity type: Research Organisations
Contact the organisation
ISTITUTO SUPERIORE DI SANITA
Viale Regina Elena 299
00161 ROMA
Italy

**Activity type:** Research Organisations

Contact the organisation

EU contribution: EUR 389 700

POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH
DONAUSTRASSE 99
3400 KLOSTERNEUBURG
Austria

**Activity type:** Private for-profit entities (excluding Higher or Secondary Education Establishments)

Contact the organisation

EU contribution: EUR 3 449 000

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA
CARRER ROSSELLO 149
08036 BARCELONA
Spain

**Activity type:** Research Organisations

Contact the organisation

EU contribution: EUR 629 000

Academisch Medisch Centrum bij de Universiteit van Amsterdam
MEIBERGDREEF 9
1105AZ AMSTERDAM
Netherlands

**Activity type:** Higher or Secondary Education Establishments

Contact the organisation

EU contribution: EUR 571 500

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
RUE LEBLANC 25
75015 PARIS 15
France

**Activity type:** Research Organisations

Administrative contact: Simone Mergui
Tel.: +33 1 46 54 93 64
Fax: +33 1 42 53 98 51
Contact the organisation

EU contribution: EUR 1 390 635
OSPEDALE SAN RAFFAele SRL
VIA OLGETTINA 60
20132 MILANO
Italy
See on map

**Activity type:** Private for-profit entities (excluding Higher or Secondary Education Establishments)

**EU contribution:** EUR 669,938,75

UNIVERSITE JOSEPH FOURIER GRENOBLE
Avenue Centrale, Domaine Universitaire 621
38041 GRENOBLE
France
See on map

**Activity type:** Higher or Secondary Education Establishments

**EU contribution:** EUR 0

UNIVERSITE GRENOBLE ALPES
621, AVENUE CENTRALE
38401 SAINT MARTIN D'HERES
France
See on map

**Activity type:** Higher or Secondary Education Establishments

**EU contribution:** EUR 612,907,50

KING'S COLLEGE LONDON
Strand
WC2R 2LS LONDON
United Kingdom
See on map

**Activity type:** Higher or Secondary Education Establishments

**EU contribution:** EUR 190,612,50

KAROLINSKA INSTITUTET
Nobels Vag 5
17177 STOCKHOLM
Sweden
See on map

**Activity type:** Higher or Secondary Education Establishments

**EU contribution:** EUR 895,561,25
UNIVERSITATSKLINIKUM ERLANGEN
MAXIMILIANSPLATZ 2
91054 ERLANGEN
Germany
See on map

Activity type: Higher or Secondary Education Establishments
Contact the organisation

THE UNIVERSITY OF WESTERN ONTARIO
RICHMOND STREET NORD - SUITE 2 1151
N6A 3K7 ONTARIO -LONDON
Canada
See on map

Activity type: Higher or Secondary Education Establishments
Contact the organisation

NEMZETI ELELMISZERLANC-BIZTONSAGI HIVATAL
KELETI KAROLY UTCA 24
1024 BUDAPEST
Hungary
See on map

Activity type: Research Organisations
Contact the organisation

LUDWIG BOLTZMANN GESELLSCHAFT GMBH
NUSSDORFER STRASSE 64 6 STOCK
1090 WIEN
Austria
See on map

Activity type: Research Organisations
Contact the organisation

BIONTECH RNA PHARMACEUTICALS GMBH
AN DER GOLDGRUBE 12
55131 MAINZ
Germany
See on map

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact the organisation
INSTITUTO DE SALUD CARLOS III
MONFORTE DE LEMOS 5
28029 MADRID
Spain
See on map
Activity type: Research Organisations
Contact the organisation

EU contribution: EUR 403,828,75

STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE THE NETHERLANDS
VAN DIEMENSTRAAT 20, 200 UNIT 48
1013 NH AMSTERDAM
Netherlands
See on map
Activity type: Other
Contact the organisation

EU contribution: EUR 0

UNIVERSITY OF MELBOURNE
PARKVILLE OFFICE OF THE VICE CHANCELLOR
3010 MELBOURNE
Australia
See on map
Activity type: Higher or Secondary Education Establishments
Contact the organisation

EU contribution: EUR 0

UNIVERSITY OF NEW SOUTH WALES
ANZAC PARADE
2052 SYDNEY
Australia
See on map
Activity type: Higher or Secondary Education Establishments
Contact the organisation

EU contribution: EUR 0

GENOME RESEARCH LIMITED
THE GIBBS BUILDING, EUSTON ROAD 215
NW1 2BE LONDON
United Kingdom
See on map
Activity type: Research Organisations
Contact the organisation

EU contribution: EUR 0
INTERNATIONAL AIDS VACCINE INITIATIVE INC
125 BROAD STREET, 9TH FLOOR
10004 NEW YORK
United States

EU contribution: EUR 626 000

Activity type: Research Organisations
Contact the organisation

UNIVERSITY OF SOUTHAMPTON
Highfield
SO17 1BJ SOUTHAMPTON
United Kingdom

EU contribution: EUR 210 343,75

Activity type: Higher or Secondary Education Establishments
Contact the organisation

Last updated on 2017-08-17
Retrieved on 2018-10-30

© European Union, 2018